Abstract
TP53 is frequently mutated in different types of neoplasms including leukemia and lymphomas. Mutations of TP53 have also been reported in mycosis fungoides (MF), the most common type of cutaneous lymphoma. However, little is known about the frequency, spectrum of mutations, and their prognostic significance in MF. In this study, we have optimized the protocol for Sanger sequencing of TP53 using DNA extracted from archival paraffin-embedded biopsies. Of 19 samples from patients with stage IIB MF or higher, 31% harbored mutations in TP53. Overall survival of the patients with mutated TP53 was significantly shorter than median survival in the age- and stage-matched patients treated in our Institution. Distribution of mutations was heterogenous in TP53 exons; however, C > T transitions were common suggesting the causal role of ultraviolet radiation. We propose that TP53 mutation status would be useful for risk stratification of patients with advanced MF.
Introduction
Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL) and in most cases runs an indolent course. However, approximately 20% of patients would progress to a widespread disease with multiple skin tumors and extracutaneous involvement with dire outcome (1). Male gender, young age, and folliculotropic subtype are risk factors for progression, but their predictive value is low (1, 2). There are currently no robust biomarkers that predict the course of the disease.
The tumor suppressor gene TP53 is central in tumorigenesis and regarded as a master regulator of several signaling pathways involved in this process. TP53 is mutated in more than 50–70% of all solid tumors and in approximately 10–20% in hematological malignancies (3). While low-grade lymphoid neoplasms reveal low p53 mutation rates, lymphomas and leukemias (in particular chronic lymphatic leukemia) with an aggressive clinical course demonstrate higher frequencies (4–7). To this end, a strong correlation was found between p53 functional status and clinical outcomes in lymphoma, such as mortality or resistance to chemotherapy (8, 9). TP53 may be mutated in a proportion of patients with another type of CTCL, Sezary syndrome, but mutations are not predictive for the course of the disease (10). Less is known about TP53 gene status in MF. Previous studies suggested that p53 overexpression and mutation is uncommon in early MF (11–13) but can be found in advanced stages indicating prognostic significance (14, 15). It has also been suggested that p53 mutations in MF are caused by ultraviolet radiation (11, 14, 16). Therefore, in this study we wished to elucidate the frequency and potential role of TP53 mutations in MF according to disease stage and course. We have developed a method, which enables TP53 sequencing from paraffin-embedded samples from a relatively large number of patient samples.
Materials and Methods
Materials
In this retrospective study, we reviewed clinical data and histopathology of 157 patients diagnosed with MF in Denmark from 1980 to 2013 and registered in the Danish pathology registry database (Patobank) and The Danish Cutaneous Lymphoma Database.1 The diagnosis was made by correlation between clinical findings and histological examination of skin biopsies (17). Staging was performed according to ISCL/EORTC criteria (18). Also, 30 patients had MF stage IIB or higher, and tissue for p53 analysis was available in 19 cases (Table 1). Control materials included CTCL cell lines SeAx, MyLa200, and MF1885, together with biopsies from solid tumors with known p53 mutations (19).
Table 1
| No. | Gender/age (years) | Clinical stage | Mutation status of TP53 | Disease duration at highest stage |
|---|---|---|---|---|
| 1 | Male/67 | T3N3M1B0 | Mutated: exon 4: c.100C > T (p.P34S); exon 4: c.254C > T (p.P85L); exon 4: c.430C > T (p.Q144stop) | 7 years, DOD |
| 2 | Female/91 | T3N0M0B0 | Mutated: exon 8: c.811G > A (p.E271K); exon 5 and 6 unable to amplify | 1 year, DOD |
| 3 | Female/67 | T4N3M0B2 | No mutations | 10 years, DOD |
| 4 | Male/72 | T3N2M0B0 | No mutations | 2 years, AWD |
| 5 | Female/89 | T3N0M0B0 | No mutations | 8 years, DOC |
| 6 | Female/56 | T4N1M0B1 | No mutations | 5 years, DOD |
| 7 | Male/69 | T3N3M1B0 | No mutations: exon 5 and 6 unable to amplify | 3 years, DOD |
| 8 | Male/76 | T4N3M0B1a | No mutations | 3 years, DOD |
| 9 | Female/65 | T3N1M0B0 | No mutations | 14 years, AWD |
| 10 | Male/83 | T3N0M0B0 | No mutations | 11 years, AWD |
| 11 | Female/55 | T3N0M0B0 | No mutations | 5 years, AWD |
| 12 | Male/75 | T3N0M0B0 | No mutations in exon 7, 10: exon 4, 5, 6, 8, and 9 unable to amplify | 3 years, DOC |
| 13 | Male/64 | T4N3M0B2 | Mutated: exon 5: c.449C > T (p.T150I) | 4 years, DOD |
| 14 | Female/74 | T3N0M0B0 | No mutations | 6 years, AWD |
| 15 | Female/71 | T3N0M0B0 | No mutations | 12 years, AWD |
| 16 | Female/63 | T3N3M0B0 | No mutations: exon 4, 5, and 6 unable to amplify | 5 years, DOC |
| 17 | Male/76 | T3N0M1B0 | Mutated: exon 5: c. 502C > T (p.H168Y); exon 5: c. 530C > A (p.P178H); exon 6: c. 670G > T (p.E224Stop) | 3 years, DOD |
| 18 | Male/99 | T3N0M0B0 | Mutated: exon 8: c.818G > A (p.R273H) | 2 years, DOC |
| 19 | Male/66 | T3N2M0B0 | Mutated: exon 5: c.457C > T (p.P153S); exon 5: c.461G > A (p.G154D) | 5 years, DOD |
Patients with MF included in mutation analysis of TP53.
AWD, alive with disease; DOD, dead of disease; DOC, dead of other causes.
TP53 Sequencing
Genomic DNA was extracted from 4 μm × 5 μm paraffin-embedded biopsies from lesional skin and purified using the DNA Sample Preparation Kit (Roche Life Science, Basel, Switzerland) according to the manufacturer’s instructions. Concentration and purity was measured on a Nanodrop 2000 instrument. PCR amplification of TP53 exon 4–10 is performed in five separate nested PCR reactions according to Table 2. The primers are designed using Primer 3 software (20, 21) and purchased from MWG Eurofins.2 The nest 1 reactions contained, in a volume of 15 μl, 0.33 μmol/l of each nest 1 primer, 7.5 μl RedEx PCR master mix (Sigma-Aldrich, St Louis, MO, USA) and 50–100 ng genomic DNA and was amplified using the following PCR conditions: initial denaturating at 95°C for 5 min, 25 cycles at 95°C for 30 s, 55°C for 30 s, and 72°C for 30 s, and a final extension at 72°C for 10 min. The nest 2 reactions contained, in a volume of 50 μl, 0.4 μM of each nest 2 primer, 25 μl RedEx PCR master mix (Sigma-Aldrich) and 1 μl 100-fold diluted nest 1 product. The nest 2 PCR conditions were the same as for the nest 1 reactions except that a total of 35 cycles were used. All five nest 1 and nest 2 reactions uses the same amplification settings. The PCR products were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany). Sequence reactions were carried out using T3 and T7 primers, 25 ng purified PCR products, and BigDye Terminator 3.1 Cycle Sequencing Kit chemistry (Life Technologies, Carlsbad, CA, USA) for BigDye incorporation and were subsequently sequenced on an ABI3500DX DNA sequenator according to the manufacturer’s instructions.
Table 2
| Exon | Primer sequence | Fragment (bp) | |
|---|---|---|---|
| 4 | F-N1 | 5′-CCATGGGACTGACTTTCTGC | 534 |
| R-N1 | 5′-GAGGAATCCCAAAGTTCCAA | ||
| F-N2 | 5′-CTGGTAAGGACAAGGGTTGG | 457 | |
| R-N2 | 5′-AGAAATGCAGGGGGATACG | ||
| 5 + 6 | F-N1 | 5′-GGAGGTGCTTACGCATGTTT | 588 |
| R-N1 | 5′-GGGAGGTCAAATAAGCAGCA | ||
| F-N2 | 5′-GCCGTCTTCCAGTTGCTTTA | 506 | |
| R-N2 | 5′-GCCACTGACAACCACCCTTA | ||
| 7 | F-N1 | 5′-CCTGCTTGCCACAGGTCT | 294 |
| R-N1 | 5′-TGATGAGAGGTGGATGGGTAG | ||
| F-N2 | 5′-TGCTTGCCACAGGTCTCC | 236 | |
| R-N2 | 5′-GGTCAGAGGCAAGCAGAGG | ||
| 8 + 9 | F-N1 | 5′-GGGAGTAGATGGAGCCTGGT | 486 |
| R-N1 | 5′-CCCCAATTGCAGGTAAAACA | ||
| F-N2 | 5′-GGGACAGGTAGGACCTGATTT | 431 | |
| R-N2 | 5′-AAGAAAACGGCATTTTGAGTG | ||
| 10 | F-N1 | 5′-TGCATGTTGCTTTTGTACCG | 300 |
| R-N1 | 5′-GAAGGCAGGATGAGAATGGA | ||
| F-N2 | 5′-TGCATGTTGCTTTTGTACCG | 263 | |
| R-N2 | 5′-CCTAGGAAGGCAGGGGAGTA |
Primer sequences for sequencing of TP53 exon 4–10.
The nest 2 primers contain T3 and T7 tags on F-N2 and R-N2, respectively.
Statistical Analysis
The overall survival (time in years from the diagnosis to death of any cause or to the last observation) was calculated for all 30 patients with stage >IIB MF. Cox logistic regression was performed using SPSS statistical package (version 22, IBM Corporation, Armonk, North Castle, NY, USA) using enter, forward, or backward methods. Kaplan–Meier plot was generated in SPSS to compare survival curves between patients with mutated and germline P53. p ≤ 0.05 was considered significant.
Results
In 6 out of 19 cases (31%), 1 or several mutations could be identified, exhibiting a heterogeneous pattern with mutations in different exons at various codon sites (Table 1).
To investigate whether TP53 mutations had impact on survival, we compared patients with mutated and normal TP53 by Kaplan–Meier analysis. Because the sample size was small, we decided to compare survival of the 6 patients with mutated p53 to all 30 patients with stage >IIB MF treated in our center in the same time frame (14 women, 16 men; mean age 71.8 years, SD 12.6). As shown in Figure 1, patients with mutated TP53 had a shorter survival than the controls. The statistically significant difference (p = 0.05) was maintained when data were adjusted to age, stage, and gender by Cox logistic regression. Adjusted odds ratio for death in the presence of mutated P53 was 2.99 (95% confidence interval 1.12–8.00, Cox regression) comparing to the control group.
Figure 1
Discussion
The protocol developed in this study allowed for PCR amplification and Sanger sequencing of TP53 in archival formalin-fixed and paraffin-embedded samples of MF. Only in 4 out of 19 samples, we were unable to amplify one or several exons, which is most probably due to sample age and DNA crosslinking.
The frequency of mutations in stage IIB or higher was 31%, which is similar to what has been reported previously (11, 16). In contrast, no mutations have been identified in a recent study of McGirt et al. (14) who reported Pro72Arg polymorphism to be more common in MF. Mutation analysis did not reveal any distinctive pattern of alterations in TP53. None of the earlier reported mutations were identical to our findings, and our cases harbored only one of the known hotspot mutations (R273H in case 18). In a recent study, Choi et al. reported 7 different mutations located at different sites in 7 out of 40 analyzed patients, including the well-known R273H hotspot (22). Our cases revealed mainly missense single nucleotide mutations resulting in stop codons (cases 1 and 17). Frequent C > T transitions seem to support the hypothesis that TP53 mutations demonstrate an UV B signature, which might be related to the effect of phototherapy given repeatedly in the earlier stages of the disease (11, 14, 16).
TP53 mutations seem to be associated with worse outcome (higher overall mortality). However, this analysis should be interpreted with caution since our sample is small, and the presence of mutations may reflect more intensive use of phototherapy in patients with aggressive, difficult to control disease. Larger sample and careful matching with the control patients with normal TP53 status will be required to elucidate this issue.
Statements
Author contributions
Design of the study: RG, LG, and LM; data collection: LM, ER, LG, and RG; analysis of data and full access to raw data: RG, LG, and LM; drafting of the manuscript: GW, LM, LG, and RG; and revision of manuscript for important intellectual content: RG, LG, LM, GW, and ER.
Funding
This study was funded from the operational grant from Bispebjerg Hospital and research grant from Aage Bangs Foundation, Copenhagen, Denmark.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer [UK] and handling Editor declared their shared affiliation, and the handling Editor states that the process nevertheless met the standards of a fair and objective review.
References
1
AgarNSWedgeworthECrichtonSMitchellTJCoxMFerreiraSet alSurvival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol (2010) 28(31):4730–9.10.1200/JCO.2009.27.7665
2
ScarisbrickJJPrinceHMVermeerMHQuaglinoPHorwitzSPorcuPet alCutaneous Lymphoma International Consortium Study of outcome in advanced stages of Mycosis Fungoides and Sezary Syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol (2015) 33(32):3766–73.10.1200/JCO.2015.61.7142
3
RivlinNBroshROrenMRotterV. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer (2011) 2(4):466–74.10.1177/1947601911408889
4
BaliakasPHadzidimitriouASuttonLARossiDMingaEVillamorNet alRecurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia (2015) 29(2):329–36.10.1038/leu.2014.196
5
GuiezeRRobbePCliffordRde GuibertSPereiraBTimbsAet alPresence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood (2015) 126(18):2110–7.10.1182/blood-2015-05-647578
6
MalcikovaJStano-KozubikKTichyBKantorovaBPavlovaSTomNet alDetailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia (2015) 29(4):877–85.10.1038/leu.2014.297
7
RossiDKhiabanianHSpinaVCiardulloCBruscagginAFamaRet alClinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood (2014) 123(14):2139–47.10.1182/blood-2013-11-539726
8
Xu-MonetteZYMedeirosLJLiYOrlowskiRZAndreeffMBueso-RamosCEet alDysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood (2012) 119(16):3668–83.10.1182/blood-2011-11-366062
9
Xu-MonetteZYWuLViscoCTaiYCTzankovALiuW-Met alMutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood (2012) 120(19):3986–96.10.1182/blood-2012-05-433334
10
WoollardWJPullabhatlaVLorencAPatelVMButlerRMBayegaAet alCandidate driver genes in Sezary syndrome: frequent perturbations of genes involved in genome maintenance and DNA repair. Blood (2016) 127(26):3387–97.10.1182/blood-2016-02-699843
11
McGregorJMCrookTFraser-AndrewsEARozyckaMCrosslandSBrooksLet alSpectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest Dermatol (1999) 112(3):317–21.10.1046/j.1523-1747.1999.00507.x
12
KapurSMenkeMATiemannMSchubertCParwareschR. Early mycosis fungoides: molecular analysis for its diagnosis and the absence of p53 gene mutations in cases with progression. J Dermatol Sci (2001) 26(1):36–45.10.1016/S0923-1811(00)00159-6
13
DereureOLeviEVonderheidECKadinME. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol (2002) 118(6):949–56.10.1046/j.1523-1747.2002.01794.x
14
McGirtLYJiaPBaerenwaldDADuszynskiRJDahlmanKBZicJAet alWhole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood (2015) 126(4):508–19.10.1182/blood-2014-11-611194
15
LiGChoobackLWolfeJTRookAHFelixCALessinSRet alOverexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. J Invest Dermatol (1998) 110(5):767–70.10.1046/j.1523-1747.1998.00167.x
16
WhittakerS. Molecular genetics of cutaneous lymphomas. Ann N Y Acad Sci (2001) 941:39–45.10.1111/j.1749-6632.2001.tb03709.x
17
PimpinelliNOlsenEASantucciMVonderheidEHaeffnerACStevensSet alDefining early mycosis fungoides. J Am Acad Dermatol (2005) 53(6):1053–63.10.1016/j.jaad.2005.08.057
18
OlsenEVonderheidEPimpinelliNWillemzeRKimYKnoblerRet alRevisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca. Blood (2007) 110(6):1713–22.10.1182/blood-2007-03-055749
19
ManfeVBiskupEJohansenPKamstrupMRKrejsgaardTFMorlingNet alMDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53. J Invest Dermatol (2012) 132(5):1487–96.10.1038/jid.2012.10
20
UntergasserACutcutacheIKoressaarTYeJFairclothBCRemmMet alPrimer3 – new capabilities and interfaces. Nucleic Acids Res (2012) 40(15):e115.10.1093/nar/gks596
21
KoressaarTRemmM. Enhancements and modifications of primer design program Primer3. Bioinformatics (2007) 23(10):1289–91.10.1093/bioinformatics/btm091
22
ChoiJGohGWalradtTHongBSBunickCGChenKet alGenomic landscape of cutaneous T cell lymphoma. Nat Genet (2015) 47(9):1011–9.10.1038/ng.3356
Summary
Keywords
p53 mutation, mycosis fungoides, survival rate, sequencing data analysis, cutaneous lymphoma
Citation
Wooler G, Melchior L, Ralfkiaer E, Rahbek Gjerdrum LM and Gniadecki R (2016) TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides. Front. Med. 3:51. doi: 10.3389/fmed.2016.00051
Received
13 June 2016
Accepted
19 October 2016
Published
11 November 2016
Volume
3 - 2016
Edited by
Mette Søndergaard Deleuran, Aarhus University Hospital, Denmark
Reviewed by
Uffe Koppelhus, Skejby Sygehus, Denmark; Adriana Van Marion, VieCuri Medisch Centrum, Netherlands
Updates
Copyright
© 2016 Wooler, Melchior, Ralfkiaer, Rahbek Gjerdrum and Gniadecki.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Robert Gniadecki, r.gniadecki@gmail.com
Specialty section: This article was submitted to Dermatology, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.